Dialogues in Clinical Neuroscience最新文献_第6页

Selected Bibliography 选定的参考书目

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-12-31 DOI: 10.36019/9781978814950-011

引用次数: 0

Between the Lines The Intermediality of Ilya Kabakov’s Albums 字里行间:伊利亚·卡巴科夫专辑的中间性

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-12-31 DOI: 10.36019/9781978814950-004

引用次数: 0

Cannabinoids: for better and for worse . 大麻素:是好是坏 。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/fthibaut

Florence Thibaut, Margret R Hoehe

引用次数: 4

History of cannabis and the endocannabinoid system . 大麻和内源性大麻素系统的历史 。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/mcrocq

Marc-Antoine Crocq

{"title":"History of cannabis and the endocannabinoid system\u2029.","authors":"Marc-Antoine Crocq","doi":"10.31887/DCNS.2020.22.3/mcrocq","DOIUrl":"https://doi.org/10.31887/DCNS.2020.22.3/mcrocq","url":null,"abstract":"This article retraces the story of cannabis from the earliest contacts of humans with the plant to its subsequent global expansion, its medicinal uses, and the discovery of the endocannabinoid system in the 20th century. Cannabis was attested to around 12 000 years ago near the Altai Mountains in Central Asia, and since then, cannabis seeds have accompanied the migration of nomadic peoples. Records of the medicinal use of cannabis appear before the Common Era in China, Egypt, and Greece (Herodotus), and later in the Roman empire (Pliny the Elder, Dioscorides, Galen). In the 19th century, orientalists like Silvestre de Sacy, and Western physicians coming into contact with Muslim and Indian cultures, like O'Shaughnessy and Moreau de Tours, introduced the medicinal use of cannabis into Europe. The structure of the main psychoactive phytocannabinoid, tetrahydrocannabinol (THC), was determined in Israel by Mechoulam and Gaoni in 1964. This discovery opened the gate for many of the subsequent developments in the ﬁeld of endocannabinoid system (ECS) research. The advances in the scientific knowledge of the ECS place the debate on cannabis liberalization in a new context.\u2029.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"22 3","pages":"223-228"},"PeriodicalIF":8.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/18/DialoguesClinNeurosci-22-223.PMC7605027.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38586547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 64

Neurobiology of cannabinoid receptor signaling . 大麻素受体信号的神经生物学 。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/blutz

Beat Lutz

{"title":"Neurobiology of cannabinoid receptor signaling\u2029.","authors":"Beat Lutz","doi":"10.31887/DCNS.2020.22.3/blutz","DOIUrl":"https://doi.org/10.31887/DCNS.2020.22.3/blutz","url":null,"abstract":"The endocannabinoid system (ECS) is a highly versatile signaling system within the nervous system. Despite its widespread localization, its functions within the context of distinct neural processes are very well discernable and specific. This is remarkable, and the question remains as to how such specificity is achieved. One key player in the ECS is the cannabinoid type 1 receptor (CB1), a G protein-coupled receptor characterized by the complexity of its cell-specific expression, cellular and subcellular localization, and its adaptable regulation of intracellular signaling cascades. CB1 receptors are involved in different synaptic and cellular plasticity processes and in the brain's bioenergetics in a context-specific manner. CB2 receptors are also important in several processes in neurons, glial cells, and immune cells of the brain. As polymorphisms in ECS components, as well as external impacts such as stress and metabolic challenges, can both lead to dysregulated ECS activity and subsequently to possible neuropsychiatric disorders, pharmacological intervention targeting the ECS is a promising therapeutic approach. Understanding the neurobiology of cannabinoid receptor signaling in depth will aid optimal design of therapeutic interventions, minimizing unwanted side effects.\u2029.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"22 3","pages":"207-222"},"PeriodicalIF":8.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/5c/DialoguesClinNeurosci-22-207.PMC7605026.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38586548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 37

Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions . 大麻素和内源性大麻素系统在奖励处理和成瘾:从机制到干预 。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/rspanagel

Rainer Spanagel

{"title":"Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions\u2029.","authors":"Rainer Spanagel","doi":"10.31887/DCNS.2020.22.3/rspanagel","DOIUrl":"https://doi.org/10.31887/DCNS.2020.22.3/rspanagel","url":null,"abstract":"The last decades have seen a major gain in understanding the action of cannabinoids and the endocannabinoid system in reward processing and the development of addictive behavior. Cannabis-derived psychoactive compounds such as Δ9-tetrahydrocannabinol and synthetic cannabinoids directly interact with the reward system and thereby have addictive properties. Cannabinoids induce their reinforcing properties by an increase in tonic dopamine levels through a cannabinoid type 1 (CB1) receptor-dependent mechanism within the ventral tegmental area. Cues that are conditioned to cannabis smoking can induce drug-seeking responses (ie, craving) by eliciting phasic dopamine events. A dopamine-independent mechanism involved in drug-seeking responses involves an endocannabinoid/glutamate interaction within the corticostriatal part of the reward system. In conclusion, pharmacological blockade of endocannabinoid signaling should lead to a reduction in drug craving and subsequently should reduce relapse behavior in addicted individuals. Indeed, there is increasing preclinical evidence that targeting the endocannabinoid system reduces craving and relapse, and allosteric modulators at CB1 receptors and fatty acid amide hydrolase inhibitors are in clinical development for cannabis use disorder. Cannabidiol, which mainly acts on CB1 and CB2 receptors, is currently being tested in patients with alcohol use disorder and opioid use disorder.\u2029.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"22 3","pages":"241-250"},"PeriodicalIF":8.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6a/ea/DialoguesClinNeurosci-22-241.PMC7605022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38683365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 37

Cannabis points to the synaptic pathology of mental disorders: how aberrant synaptic components disrupt the highest psychological functions . 大麻指出了精神疾病的突触病理学:异常的突触成分如何破坏最高的心理功能 。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/pmorrison

Paul D Morrison, Robin M Murray

{"title":"Cannabis points to the synaptic pathology of mental disorders: how aberrant synaptic components disrupt the highest psychological functions\u2029.","authors":"Paul D Morrison, Robin M Murray","doi":"10.31887/DCNS.2020.22.3/pmorrison","DOIUrl":"https://doi.org/10.31887/DCNS.2020.22.3/pmorrison","url":null,"abstract":"Cannabis can elicit an acute psychotic reaction, and its long-term use is a risk factor for schizophrenia. The main active psychoactive ingredient ∆9-tetrahydrocannabinol (Δ9-THC) activates cannabinoid 1 (CB1) receptors, which are localized to the terminals of glutamate and GABA neurons in the brain. The endogenous cannabinoids are involved in information processing and plasticity at synapses in the hippocampus, basal ganglia, and cerebral cortex. Exogenously applied CB1 receptor agonists disrupt neuronal dynamics and synaptic plasticity, resulting in cognitive deficits and impairment of the highest psychological functions. Various other pro-psychotic drugs, such as ketamine and methamphetamine, exert their effects in the same microdomain of synaptic spines as Δ9-THC. Additionally, many of the most robust findings in psychiatric genetics include components that localize to dendritic spines and have important roles in information processing and plasticity.\u2029.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"22 3","pages":"251-258"},"PeriodicalIF":8.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a4/f2/DialoguesClinNeurosci-22-251.PMC7605021.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38683366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Cannabinoids and their therapeutic applications in mental disorders . 大麻素及其在精神疾病中的治疗应用 .

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/pfadda

Maria Scherma, Anna Lisa Muntoni, Gernot Riedel, Walter Fratta, Paola Fadda

{"title":"Cannabinoids and their therapeutic applications in mental disorders\u2029.","authors":"Maria Scherma, Anna Lisa Muntoni, Gernot Riedel, Walter Fratta, Paola Fadda","doi":"10.31887/DCNS.2020.22.3/pfadda","DOIUrl":"10.31887/DCNS.2020.22.3/pfadda","url":null,"abstract":"Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the endocannabinoid system and its role in multiple physiological processes, both natural and synthetic cannabinoids have attracted considerable interest as putative medications in pathological conditions such as, but not exclusive to, mental disorders. Here, we provide a summary of cannabinoid effects in support of possible therapeutic applications for major depression, bipolar disorder, anxiety, posttraumatic stress disorder, and schizophrenia. Considering this evidence, highlighted benefits and risks of cannabinoid use in the management of these illnesses require further experimental study.\u2029.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"22 3","pages":"271-279"},"PeriodicalIF":8.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/da/0e/DialoguesClinNeurosci-22-271.PMC7605020.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38683368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The costs and benefits of cannabis control policies . 大麻管制政策的成本与收益 .

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/whall

Wayne Hall

{"title":"The costs and benefits of cannabis control policies\u2029.","authors":"Wayne Hall","doi":"10.31887/DCNS.2020.22.3/whall","DOIUrl":"10.31887/DCNS.2020.22.3/whall","url":null,"abstract":"As is the case for most drugs, cannabis use has costs and benefits, and so do the policies that attempt to minimize the first and maximize the second. This article summarizes what we know about the harmful effects of recreational cannabis use and the benefits of medical cannabis use under the policy of prohibition that prevailed in developed countries until 2012. It outlines three broad ways in which cannabis prohibition may be relaxed, namely, the depenalization of personal possession and use, the legalization of medical use, and the legalization of adult recreational use. It reviews evidence to date on the impacts of each of these forms of liberalization on the costs and benefits of cannabis use. It makes some plausible conjectures about the future impacts of the commercialization of cannabis using experience from the commercialization of the alcohol, tobacco, and gambling industries. Cannabis policy entails unavoidable trade-offs between competing social values in the face of considerable uncertainty about the effects that more liberal cannabis policies will have on cannabis use and its consequences for better or worse.\u2029.","PeriodicalId":54343,"journal":{"name":"Dialogues in Clinical Neuroscience","volume":"22 3","pages":"281-287"},"PeriodicalIF":8.3,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/33/DialoguesClinNeurosci-22-281.PMC7605025.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38683369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The legalization of cannabinoid products and standardizing cannabis-drug development in the United States: a brief report . 美国大麻素产品合法化和大麻药物开发标准化:简要报告 。

IF 8.3 2区医学

Dialogues in Clinical Neuroscience Pub Date : 2020-09-01 DOI: 10.31887/DCNS.2020.22.3/jmarcu

Jahan Marcu

引用次数: 5